



Announcement Summary

Entity name

PHARMAUST LIMITED

Announcement Type

New announcement

Date of this announcement

5/9/2024

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Unlisted Options	384,000
PAA	ORDINARY FULLY PAID	54,847

Proposed +issue date

25/10/2024

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

PHARMAUST LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

35094006023

1.3 ASX issuer code

PAA

1.4 The announcement is

New announcement

1.5 Date of this announcement

5/9/2024

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	9/10/2024	Estimated	

Comments

Proposed issuance of 54,847 Shares to Dr Thomas Duthy (and/or his nominee), a former NED of the Company, pursuant to Resolution 19 of the Company's Notice of Annual General Meeting dated 5 September 2024, subject to shareholder approval.

Proposed issuance of 384,000 Options to Dr Thomas Duthy (and/or his nominee), a former NED of the Company, pursuant to Resolution 20 of the Company's Notice of Annual General Meeting dated 5 September 2024, subject to shareholder approval.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ASX +security code and description

PAA : ORDINARY FULLY PAID

Number of +securities proposed to be issued

54,847

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

**Please describe the consideration being provided for the +securities**

Settlement of accrued former Director's fees for the period 5 February 2024 to 9 May 2024, at a deemed issue price of \$0.2282 per share.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

12,516.130000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

New class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?

No

Will the entity be seeking quotation of the 'new' class of +securities on ASX?

No

ASX +security code

New class-code to be confirmed

+Security description

Unlisted Options

+Security type

Options

Number of +securities proposed to be issued

384,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Satisfaction of the Company's obligations under Dr Thomas Duthy's engagement letter. Refer to Resolution 20 of the Notice of Annual General Meeting dated 5 September 2024 for further details.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

48,000.000000

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes



Options details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.2600	5/2/2028

Details of the type of +security that will be issued if the option is exercised

PAA : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One (1) fully paid ordinary share for every one (1) option exercised.

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02849004-6A1224051&v=fc9bdb61fe50_ea61f8225e24ce041a0e155a9400

Part 7C - Timetable

7C.1 Proposed +issue date

25/10/2024

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
No**7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**
No**7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**
No**7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?**
Yes**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**
No**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**
No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?
No**7E.2 Is the proposed issue to be underwritten?**



No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

54,847 Shares proposed to be issued in settlement of accrued former Director's fees to Dr Thomas Duthy.

384,000 Options proposed to be issued as satisfaction of the Company's obligations under Dr Thomas Duthy's engagement letter.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)